space space   
 

News

 2007 | 2006 | 2005 | Archived
   

Gemin X Pharmaceuticals, Inc. Appoints Eric Roberts to Board of Directors

Montréal, QC and Malvern, PA – Oct 1, 2007 – Gemin X Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on developing novel treatments for cancer, is pleased to announce the appointment of Eric W. Roberts to its Board of Directors.

Mr. Roberts is currently Managing Director of Caxton Advantage. From 2000 to 2003, he was Managing Director and Co-Head of the Global Healthcare Investment Banking Group at Lehman Brothers and was previously Head of Life Sciences Investment Banking at UBS and Dillon, Read & Co. Inc. Mr. Roberts is a co-founder of Caxton Advantage, along with A. Rachel Leheny, the former Senior Biotechnology Analyst at Lehman Brothers, UBS and Hambrecht & Quist.

"Mr. Roberts' extensive experience and expertise in finance and capital markets for the healthcare industry make him a valuable addition to our Board as we emerge from a development-stage company to a pharmaceutical products company" said Dr. Robert G. McNeil, Chairman of the Board.

"Gemin X is an exciting Company that has great potential to make an impact on the lives of cancer patients" stated Mr. Roberts. "They have generated exciting human clinical data with their lead drug candidate, obatoclax, a novel small molecule Bcl-2 pan inhibitor which has been tested in a range of hematological and solid tumor cancers."

About Gemin X

Gemin X Pharmaceuticals, Inc., through its wholly-owned subsidiary Gemin X Biotechnologies Inc., specializes in the discovery and development of target-based novel cancer therapeutics. Gemin X's lead product, obatoclax (GX15-070), is a small molecule, pan-inhibitor of Bcl-2 proteins and is currently in Phase 2 clinical trials. Gemin X is also developing GMX1777, a small molecule that targets cancer metabolism by a p53-independent mechanism, now in Phase 1 clinical trials. Gemin X is privately held and is located in Malvern, Pennsylvania and Montréal, Québec.

return to top